Abzu, a member of Catalonia.health, and ADViRNA, a boutique U.S.-based CRO, are joining forces to develop novel siRNA therapeutics.

The venture capital company Asabys Partners, a member of Catalonia.health, and AltamarCAM  Partners, a global investment firm specialized in private markets, have reached an agreement to integrate Aliath Bioventures, a member of Catalonia.health, the life sciences team, into Asabys and to co-manage the Alta Life Sciences Spain I FCR fund.

The packaging company Miton, a member of Catalonia.health, has obtained international B Corp certification, a recognition that distinguishes companies that meet the highest standards of sustainability, social responsibility, and transparency, and that use business as a force for positive impact on society and the environment.

Vall  d'Hebron Research Institute (VHIR), a member of Catalonia.health, and Prous Institute for Biomedical Research have signed a three-year collaboration agreement to promote high-impact research projects that form part of or are in the selection phase of the VHIR's innovation portfolio.

The biotechnology company Inbiomotion, a member of Catalonia.health, has announced the publication, in the journal Journal of Medical Economics, of a study highlighting the positive economic impact of its diagnostic tool MAF Test® in patients with early-stage breast cancer.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced its participation as a sponsor of thefirst-ever Phelan-McDermid syndrome (PMS) burden of illness study. 

The venture capital company, Ysios Capital, a member of Catalonia.health, announced that its investee VarmX has signed a strategic development agreement with global biopharmaceutical company CSL (ASX:CSL), which includes an exclusive option to purchase the company.

The biopharmaceutical company Oryzon Genomics, a member of Catalonia.health, has announced that it has been selected as a finalist in the 2025 European Lifestars  Awards in the category Post-IPO Raise of the Year for the European Mediterranean region.

The venture capital company Asabys Partners, a member of Catalonia.health, leads €10 million extension of its oversubscribed €35 million Series C financing round through its Sabadell Asabys II fund

The biotechnology company CONNECTA Therapeutics, a member of Catalonia.health, has announced the launch of studies for the paediatric development program of CTH120, an investigational FXS treatment, following positive results from the Phase I trial.